Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 11/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 10/20 | 0.64 |
| ▸ | CLK4 | Q9HAZ1 | 9/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.64 |
| ▸ | USP2 | O75604 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | GRM5 | P41594 | 2/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18398007 | 0.83 | FAAH (0.54) | CYP1A2CYP2C19CLK4ALDH1A1HSD17B10 | |
| SCHEMBL12331397 | 0.80 | GRM5 (0.62) | CYP1A2CYP2C19CLK4ALDH1A1HSD17B10 | |
| SCHEMBL23221384 | 0.79 | CLK4 (0.54) | CYP1A2CYP2C19CLK4ALDH1A1HSD17B10 | |
| SCHEMBL9792862 | 0.78 | GRM5 (0.64) | CYP1A2CYP2C19CLK4ALDH1A1HSD17B10 | |
| SCHEMBL23221369 | 0.78 | GRM5 (0.52) | CYP1A2CYP2C19CLK4ALDH1A1HSD17B10 | |
| SCHEMBL20816281 | 0.77 | CYP1A2 (0.62) | CYP1A2CYP2C19CLK4ALDH1A1HSD17B10 | |
| SCHEMBL15757631 | 0.77 | XDH (0.51) | CYP1A2CYP2C19CLK4ALDH1A1MAPK1 | |
| SCHEMBL18998665 | 0.77 | GRM5 (0.62) | CYP1A2CYP2C19CLK4ALDH1A1HSD17B10 | |
| SCHEMBL23221310 | 0.77 | FAAH (0.55) | CYP1A2CYP2C19CLK4ALDH1A1HSD17B10 | |
| SCHEMBL9792981 | 0.77 | GRM5 (0.62) | CYP1A2CYP2C19CLK4ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370784-B2 | Cyano-substituted heterocycles with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| US-20210284631-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| EP-3523291-B1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-04-14 | — | — | EP | disclosed |
| US-10624897-B2 | Chlorobenzene substituted azaaryl compounds | TAIPEI MEDICAL UNIVERSITY (TW) | 2020-04-21 | — | — | US | disclosed |
| US-10624897-B2 | Chlorobenzene substituted azaaryl compounds | TAIPEI MEDICAL UNIVERSITY (TW) | 2020-04-21 | — | — | US | disclosed |
| US-20190083499-A1 | CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS | TAIPEI MEDICAL UNIVERSITY (TW) | 2019-03-21 | — | — | US | disclosed |
| US-20190083499-A1 | CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS | TAIPEI MEDICAL UNIVERSITY (TW) | 2019-03-21 | — | — | US | disclosed |
| EP-3324970-A1 | CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS | Taipei Medical University (TW) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017015400-A1 | CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS | TAIPEI MEDICAL UNIVERSITY (TW) | 2017-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284631-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | USP30, USP28, USP1 | CYP1A2 1592/4885CYP2C19 2271/4885CLK4 2870/4885 |
| US-11370784-B2 | Cyano-substituted heterocycles with activity as inhibitors of USP30 | USP30, USP28, USP1 | CYP1A2 1592/4885CYP2C19 2271/4885CLK4 2870/4885 |
| US-10624897-B2 | Chlorobenzene substituted azaaryl compounds | MKI67, CTCF, CDKN1A | CYP1A2 95/4885CYP2C19 623/4885CLK4 2558/4885 |
| US-20190083499-A1 | CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS | MKI67, CTCF, CDKN1A | CYP1A2 95/4885CYP2C19 623/4885CLK4 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.